## Franziska Sotzny

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7944182/publications.pdf

Version: 2024-02-01

17 papers	888 citations	12 h-index	940134 16 g-index
19	19	19	1175
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). Journal of Translational Medicine, 2022, 20, 138.	1.8	116
2	Delineating the Association Between Soluble CD26 and Autoantibodies Against G-Protein Coupled Receptors, Immunological and Cardiovascular Parameters Identifies Distinct Patterns in Post-Infectious vs. Non-Infection-Triggered Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Immunology, 2021, 12, 644548.	2.2	14
3	Metformin Attenuates ROS via FOXO3 Activation in Immune Cells. Frontiers in Immunology, 2021, 12, 581799.	2.2	25
4	Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study. Journal of Clinical Medicine, 2021, 10, 2420.	1.0	5
5	Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology. Frontiers in Immunology, 2021, 12, 687449.	2.2	26
6	Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Journal of Clinical Medicine, 2021, 10, 3675.	1.0	38
7	The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in myalgic encephalomyelitis/chronic fatigue syndrome: A meta-analysis of public DNA methylation and gene expression data. Heliyon, 2021, 7, e07665.	1.4	7
8	HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients. Frontiers in Immunology, 2020, 11, 607918.	2.2	37
9	Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. ESC Heart Failure, 2020, 7, 1064-1071.	1.4	46
10	IgG stimulated $\hat{I}^22$ adrenergic receptor activation is attenuated in patients with ME/CFS. Brain, Behavior, & Immunity - Health, 2020, 3, 100047.	1.3	15
11	Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset. Frontiers in Immunology, 2020, 11, 578.	2.2	29
12	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease. Autoimmunity Reviews, 2018, 17, 601-609.	2.5	199
13	Serum Free Light Chains in CVID—a Marker for Differential Diagnosis. Journal of Clinical Immunology, 2018, 38, 163-165.	2.0	12
14	The expression signature of very long non-coding RNA in myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Translational Medicine, 2018, 16, 231.	1.8	20
15	TCF11/Nrf1-Mediated Induction of Proteasome Expression Prevents Cytotoxicity by Rotenone. Antioxidants and Redox Signaling, 2016, 25, 870-885.	2.5	33
16	Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. Journal of Clinical Investigation, 2015, 125, 4196-4211.	3.9	258
17	Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis. Frontiers in Medicine, 0, 9, .	1.2	7